News

Today, landmarks around the world will be lit up teal as advocates globally work to raise awareness — throughout this entire month — about Alzheimer’s disease. Light the World in Teal is an annual effort spearheaded by the Alzheimer’s Foundation of America (AFA) during each year’s Alzheimer’s…

NewAmsterdam Pharma has dosed the first participant in a large mid-stage clinical trial assessing the safety and effectiveness of its cholesterol-lowering treatment candidate obicetrapib as a potential aid for people with preclinical Alzheimer’s disease. The biopharmaceutical company is developing the oral med for individuals at risk of…

In the U.S., people with early Alzheimer’s disease will now have the option for at-home treatment with the approved therapy Leqembi (lecanemab) throughout the entire treatment journey. Leqembi is approved in the U.S. to treat early Alzheimer’s in adults with mild cognitive impairment or mild dementia. The originally…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions associated with Alzheimer’s disease psychosis. The FDA grants this designation to investigational medicines intended to treat serious conditions and fill an unmet…

Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatment experience in people with mild-to-moderate Alzheimer’s disease. The BEACON study evaluated provider-reported outcomes from 21 investigators treating 162 long-term care patients who received routine…

June is Alzheimer’s & Brain Awareness Month, and the Alzheimer’s Association is holding a wide range of events to raise funds to fuel research and promote awareness of Alzheimer’s disease and other forms of dementia. According to the association’s website, …

The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease. Auvelity is now the only FDA-approved treatment for Alzheimer’s-related agitation that is not classified as an antipsychotic, according to the Alzheimer’s Association. “For…

The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73) were sustained over nearly three years, according to new analysis from the treatment’s developer, Anavex Life Sciences. Patients treated with the investigational oral medication in a Phase 2b/3 study…

Researchers are calling for more studies to determine whether lymphovenous anastomosis (LVA), a surgical procedure that helps clear molecular waste from the brain, might benefit people with Alzheimer’s disease. “LVA represents a novel therapeutic strategy that may complement existing treatments, offering new hope for addressing the [disease biology] of…

The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an approved treatment for early Alzheimer’s disease. Under its current approval, patients are first given the therapy as infusions into the…